Redistribution of iron towards deposits in erythroblastopenic anemia as a consequence of decreased erythroferrone production

被引:4
作者
Cucuianu, A. [1 ]
Patiu, M. [1 ]
Trifa, A. P. [1 ]
Tomuleasa, C. [1 ]
Dima, D. [1 ]
机构
[1] Ion Chiricuta Canc Inst, Dept Hematol, Cluj Napoca 400124, Romania
关键词
MULTIPLE-MYELOMA; HEPCIDIN; INFLAMMATION; FERRITIN;
D O I
10.1016/j.mehy.2014.09.008
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Most of the body iron is found within hemoglobin in red cells (the erythron), a smaller amount being distributed in other tissues such as muscles and in deposits. Iron homeostasis is a finely tuned process in which the most important regulators are probably the liver-derived hepcidin which blocks iron absorption and directs iron towards deposits and the recently discovered erythroblast-derived erythroferrone which inhibits hepcidin synthesis and therefore increases availability of iron for hemoglobin synthesis. Hepcidin secretion is increased by inflammatory cytokines and erythroferrone production increases when there is active, expanding erythropoiesis, for example after acute blood loss. We hypothesize that in pathological situations associated with erythroid precursor suppression (erythroblastopenia), anemia is the result of two major mechanisms: (1) direct erythroblast suppression leading to decreased production of red cells and (2) low iron availability due to high hepcidin levels arising as a result of low erythroferrone production. Additionally, infectious episodes and other inflammatory conditions that often complicate the course of these diseases may further promote hepcidin synthesis through increased cytokine production leading to even lower iron availability and a vicious circle of worsening anemia. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:530 / 532
页数:3
相关论文
共 16 条
[1]   The significance of ferritin in cancer: Anti-oxidation, inflammation and tumorigenesis [J].
Alkhateeb, Ahmed A. ;
Connor, James R. .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2013, 1836 (02) :245-254
[2]  
Atanasiu V, 2006, Rom J Intern Med, V44, P25
[3]   Non-HFE hemochromatosis: Pathophysiological and diagnostic aspects [J].
Bardou-Jacquet, Edouard ;
Ben Ali, Zeineb ;
Beaumont-Epinette, Marie-Pascale ;
Loreal, Olivier ;
Jouanolle, Anne-Marie ;
Brissot, Pierre .
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2014, 38 (02) :143-154
[4]   Recycling Iron in Normal and Pathological States [J].
Beaumont, Carole ;
Delaby, Constance .
SEMINARS IN HEMATOLOGY, 2009, 46 (04) :328-338
[5]   Hepcidin and multiple myeloma related anemia [J].
Cucuianu, A ;
Patiu, M ;
Rusu, A .
MEDICAL HYPOTHESES, 2006, 66 (02) :352-354
[6]   Anemia of Chronic Disease [J].
Gangat, Naseema ;
Wolanskyj, Alexandra P. .
SEMINARS IN HEMATOLOGY, 2013, 50 (03) :232-238
[7]   SYSTEMIC IRON HOMEOSTASIS [J].
Ganz, Tomas .
PHYSIOLOGICAL REVIEWS, 2013, 93 (04) :1721-1741
[8]   The Hepcidin-Ferroportin System as a Therapeutic Target in Anemias and Iron Overload Disorders [J].
Ganz, Tomas ;
Nemeth, Elizabeta .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2011, :538-542
[9]   The Erythroid Factor Erythroferrone and Its Role In Iron Homeostasis [J].
Kautz, Leon ;
Jung, Grace ;
Nemeth, Elizabeta ;
Ganz, Tomas .
BLOOD, 2013, 122 (21)
[10]   In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2 [J].
Maes, Ken ;
Nemeth, Elizabeta ;
Roodman, G. David ;
Huston, Alissa ;
Esteve, Flavia ;
Freytes, Cesar ;
Callander, Natalie ;
Katodritou, Eirini ;
Tussing-Humphreys, Lisa ;
Rivera, Seth ;
Vanderkerken, Karin ;
Lichtenstein, Alan ;
Ganz, Tomas .
BLOOD, 2010, 116 (18) :3635-3644